Notably, patients with high-grade B cell lymphoma (HGBCL), prior exposure to anti-CD19 therapy or immunomodulatory drugs, central nervous system (CNS) involvement, or primary refractory disease were excluded. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.